Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNTO 7160 · 1 trial · 3 indications
The incidence of TEAEs from treatment until the last scheduled follow-up visit will be summarized by treatment group.
The incidence of TEAEs from treatment until the last scheduled follow-up visit will be summarized by treatment group.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose 1 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 1. |
| Part 1: Dose 2 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 2. |
| Part 1: Dose 3 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 3. |
| Part 1: Dose 4 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 4. |
| Part 1: Dose 5 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 5. |
| Part 1: Dose 6 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 6. |
| Part 1: Dose 7 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 7. |
| Part 1: Dose 8 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 8. |
| Part 1: Dose 9 | EXPERIMENTAL | Drug CNTO7160 or Placebo administered IV infusion Dose 9. |
| Part 2 (Asthma): Dose 1 | EXPERIMENTAL | Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks). |
| Part 2 (Asthma): Dose 2 | EXPERIMENTAL | Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks). |
| Part 2 (Atopic Dermatitis): Dose 1 | EXPERIMENTAL | Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks). |
| Part 2 (Atopic Dermatitis): Dose 2 | EXPERIMENTAL | Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks). |
| Name | Type | Description |
|---|---|---|
| Part 1: CNTO 7160 | DRUG | Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg). |
| Part 2 (Asthma): CNTO 7160 | DRUG | Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks). |
| Part 2 (Atopic Dermatitis): CNTO 7160 | DRUG | Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks). |
| Part 1 and Part 2: Placebo | DRUG | Participants will receive single IV infusion of placebo matched to CNTO 7160. |
Inclusion Criteria: * Part 1 (Healthy Participants): Participant must have a body weight in the range of 50 to 100 kilogram (kg) inclusive and have a body mass index (BMI) of 19 to 30 kilogram per meter square (kg/m\^2) inclusive * Part 1 (Healthy Participants): Participant must be healthy on the b...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
CNTO 7160 is an investigational small molecule being studied for the treatment of asthma, a respiratory condition. It was also evaluated in a clinical trial that included participants with atopic dermatitis. CNTO 7160 has not been approved for any indication and remains in clinical development.
CNTO 7160 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the clinical trial that evaluated the drug in healthy participants, participants with asthma, and participants with atopic dermatitis.
CNTO 7160 is in Phase 1 clinical development. The single trial conducted for this drug was a Phase 1 study, and it has been completed. CNTO 7160 is investigational and has not received FDA approval for asthma or any other indication.
CNTO 7160 was evaluated in one completed Phase 1 trial, NCT02345928. The study was a single ascending dose study in healthy participants and a multiple ascending dose study in participants with asthma and participants with atopic dermatitis. It enrolled 108 participants across Belgium and Germany.
Yes. CNTO 7160 is also referred to as Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, and Part 2: CNTO 7160. These names refer to the same investigational drug developed by Johnson & Johnson for asthma and related conditions.